Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Molenbeek-Saint-Jean – page 90

2 121 clinical trials in Molenbeek-Saint-Jean, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Molenbeek-Saint-Jean at a glance
2 121
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 121 trials in Molenbeek-Saint-Jean

Open in trial search

A Study Testing VX-407 in Patients with Autosomal Dominant Polycystic Kidney Disease Who Have Specific PKD1 Gene Changes

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:VX-407
  • Sponsor:Vertex Pharmaceuticals Inc.

Study on the Safety and Effectiveness of a UTI Vaccine (GSKVX000000046019) for Adults Aged 18-64 and Women Aged 18-64 with Urinary Tract Infections

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:GSKVX000000044501
  • Sponsor:GlaxoSmithKline Biologicals

Study on the Safety and Effects of Trastuzumab Deruxtecan with Drug Combination for Patients with Metastatic HER2-low Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study of inhaled alpha1-proteinase inhibitor (Kamada-AAT) in adults with alpha-1 antitrypsin deficiency and moderate to severe airflow limitation

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ALPHA-1-ANTITRYPSIN
  • Sponsor:Kamada Ltd.

Study of Buparlisib and Paclitaxel for Patients with Recurrent or Metastatic Head and Neck Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Buparlisib
  • Sponsor:Adlai Nortye USA Inc.

Hodgkin's disease

Not recruiting

Study Comparing Brentuximab Vedotin with Drug Combination for Treating Advanced Classical Hodgkin Lymphoma in Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin
  • Sponsor:Takeda Development Center Americas Inc.

B-cell lymphoma+1

Not recruiting

Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Study on Luspatercept for Patients with Lower-risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Celgene Corp.

B-cell lymphoma

Not recruiting

Study of Glofitamab, Atezolizumab, and Polatuzumab Vedotin for Adults with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Pulmonary sarcoidosis

Not recruiting

Study on the Effects and Safety of Namilumab for Patients with Chronic Lung Sarcoidosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Namilumab
  • Sponsor:Kinevant Sciences GmbH

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab and Golimumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Molenbeek-Saint-Jean

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. This research explores alternative treatment approaches for managing functional dyspepsia and related gastrointestinal conditions.

  • PPI Deprescribing Methods
  • Gastrointestinal Health Management
  • Alternative Treatment Strategies

Comparing effectiveness of on-demand medication use and alginate formulation therapy against traditional gradual dose reduction approaches.

02 Primary Care Innovation

Research examining optimal medication management strategies in the primary care setting, particularly focusing on patients with heartburn and reflux symptoms without clear long-term treatment indications.

  • Medication Optimization
  • Patient-Centered Care
  • Chronic Disease Management

Evaluating patient outcomes and treatment success rates across different therapeutic approaches in primary care settings.

03 Therapeutic Alternatives

Investigation into sustainable treatment options for managing gastrointestinal disorders, comparing conventional medication tapering with newer therapeutic strategies.

  • Medication Reduction Strategies
  • Alternative Therapies
  • Long-term Health Outcomes

Assessing the comparative effectiveness of different treatment approaches for chronic digestive conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.